Platelets have traditionally been understood within the context of hemostasis and hemorrhagic disorders. However, with increasing procedures being performed in smaller vessels and with an increasing incidence of atherosclerosis, the often critical role platelets play is more evident. Platelets are no longer viewed as “scaffolding” for the events of the coagulation cascade but rather as important catalysts in hemostasis, thrombosis, and fibrinolysis. Improved understanding of platelet physiology has led to developments of pharmacologic adjuncts resulting in improved patency rates and improved patient outcomes. This review addresses the physiology of platelet function and the impact of new pharmacologic agents in percutaneous intervention.
Get full access to this article
View all access options for this article.
References
1.
Kaushansky K: Thrombopoietin: The primary regulator of megakaryocyte and platelet production. Thromb Haemost74:521-525, 1995.
2.
Wagner DD, Burger PC: Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol23: 2131-2137, 2003.
3.
Phillips DR, Agin PP: Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced twodimensional gel electrophoresis. J Biol Chem252: 2121-2126, 1977.
4.
Shattil SJ, Newman PJ: Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood104: 1606-1615, 2004.
5.
French DL, Seligsohn U: Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol20:607-610, 2000.
6.
Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci117:3415-3425, 2004.
Parsson H, Norgren L, Ivancev K, et al: Thrombogenicity of metallic vascular stents in arteries and veins—an experimental study in pigs. Eur J Vasc Surg4:617-623, 1990.
9.
Farb A, Sangiorgi G, Carter AJ, et al: Pathology of acute and chronic coronary stenting in humans [see comment]. Circulation99:44-52, 1999.
10.
Ishiwata S, Tukada T, Nakanishi S, et al: Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J133:387-392, 1997.
11.
Antithrombotic Trialists C: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients [see comment] [Erratum appears in BMJ 19;324:141, 2002]. BMJ324:71-86, 2002.
12.
Catella-Lawson F: Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects. Neurology57:S5-S7, 2001.
13.
Kastrati A, von Beckerath N, Joost A, et al: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation110:1916-1919, 2004.
14.
Caplain H: Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. Cerebrovasc Dis19:214-219, 2005.
15.
Claeys MJ, Van der Planken MG, Bosmans JM, et al: Does pretreatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on periprocedural myonecrosis. Eur Heart J26:567-575, 2005.
16.
Kong D, Califf R, Miller D, et al: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation98:2829-2835, 1998.
17.
Coller B: A new murine monoclonal antibody reports an activation-dependent change in the confirmation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest76:101-108, 1985.
18.
Schneider PA: Endovascular Skills, ed 2. New York: Marcel Dekker, Inc, 2003, pp 209-210.
19.
Shammas NW: Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Intervent Radiol16:165-171, 2005.
20.
Bush RL, Lin PH, Mureebe L, et al: Routine bivalirudin use in percutaneous carotid interventions. J Endovasc Ther12:521-522, 2005.
21.
Chew DP, Lincoff AM, Gurm H, et al: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol95:581-585, 2005.
22.
Schussler JM, Cameron CS, Anwar A, et al: Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Am J Cardiol94:1417-1419, 2004.
23.
Harker LA, Marzec UM, Kelly AB, et al: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation98:2461-2469, 1998.
24.
Chan AW, Moliterno DJ, Berger PB, et al: Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: Results from the Do tirofiban and reopro give similar efficacy outcome trial (TARGET). J Am Coll Cardiol42:1188-1195, 2003.
25.
Lee SW, Park SW, Hong MK, et al: Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol95:859-862, 2005.
